Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Boehringer Ingelheim Advances Drug Plant
by Michael McCoy
April 26, 2010
| A version of this story appeared in
Volume 88, Issue 17
Boehringer Ingelheim has celebrated the topping out—the placing of the last beam—at a new facility in Ingelheim, Germany, that will produce dabigatran etexilate, the company’s new anticoagulant. Boehringer expects to complete the $160 million facility in 2011. In March 2008, the firm won European approval for dabigatran in a specialized application, but it expects to eventually market the drug, known as Pradaxa, for stroke prevention, replacing old-line treatments such as warfarin.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X